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Abstract
Background: Soluble ST2, a member of the of the Toll/IL-1 superfamily, is a novel biomarker with exceptional
predictive value in heart failure and myocardial infarction- related mortality as well as in acute dyspneic states.
Soluble ST2 is considered a decoy receptor of IL 33 that blocks the protective effects of the cytokine in
atherosclerosis and cardiac remodeling. In the present study we investigated the differences in the levels of soluble
ST2, BNP and hs-CRP between healthy controls and patients with type 2 diabetes with and without left ventricular
diastolic dysfunction. A secondary aim was to investigate correlations between sST2 and other biomarkers of type
2 diabetes, such as HbA1c.
Methods: 158 volunteers were recruited and underwent a complete Doppler-echocardiographic evaluation of both
systolic & diastolic cardiac function. All subjects with ejection fraction < 50% were excluded. The study population
was divided in 4 groups as follows: A: 42 healthy controls, B: 18 subjects without diabetes with LVDD, C: 48
patients with type 2 diabetes without LVDD & D: 50 patients with type 2 diabetes & LVDD. ELISA technique was
performed to measure sST2 levels. Statistical analysis was performed with Kruskal-Wallis & Mann-Whitney test
(continuous variables), chi squared & Fischer exact test (discrete variables), Spearman coefficient (univariate analysis)
and step-wise backward method (multivariate analysis).
Results: Patients with type 2 diabetes with (p < 0.001) or without LVDD (p = 0.007) had higher serum ST2 levels
compared to healthy controls, state found also for hs-CRP levels but not for the corresponding BNP levels (p =
0.213 & p = 0.207 respectively). Patients with type 2 diabetes & LVDD had higher serum ST2 in relation to diabetic
patients without LVDD (p = 0.001). In multivariate analysis HbA1c positively and independently correlated with sST2
levels in both groups of patients with type 2 diabetes.
Conclusions: Patients with type 2 diabetes exhibit higher sST2 levels compared to healthy controls. The presence
of LVDD in patients with type 2 diabetes is associated with even higher sST2 levels. A significant correlation
between glycemic control and sST2 levels was also revealed.
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Soluble ST2, a member of the of the Toll/IL-1 super-
family, is a novel biomarker of myocardial mechanical
stress with exceptional predictive value in heart failure
and myocardial infarction- related mortality [1-7] as
well as in acute dyspneic states [8-11]. Soluble ST2 is
considered a decoy receptor of IL 33 (a member of IL-1
receptor family of cytokines)t h a tb l o c k st h ep r o t e c t i v e
effects of the cytokine in atherosclerosis, obesity and
cardiac remodeling [3,4].
IL-33 is a cytokine with dual function, acting both as a
traditional cytokine implicated in numerous inflamma-
tory disorders and as a transcriptional factor [12].IL-33 is
expressed in various tissues and in the heart and vascular
tree and is considered to play a significant role in various
cardiovascular disorders [13]. In relation to atherosclero-
sis, IL-33 is speculated to exert an anti-atherosclerotic
effect by inducing a Th1-to-Th2 immune response [13],
arresting foam cell formation [14], stimulating IL-5 pro-
duction and oxidized low-density lipoprotein antibodies
[15]. Downstream activation of NF-kB and the MAPK
kinases by IL-33 also competitively inhibits excessive
activation of these pathways by more potent activators,
such as angiotensin II and phenylephrine, that are con-
nected to increased ROS production [16]. The role of
IL33/ST2 signaling pathway in the heart remains hugely
unveiled today and according to current knowledge it is
considered a paracrine cardioprotective pathway between
cardiomyocytes and cardiac fibroblasts [16]. In an animal
model of pressure overload, IL 33 treatment reduced car-
diac hypertrophy and fibrosis and improved survival [16].
The same cytokine also exerts antiapoptotic effects
through suppression of caspace-3 and increased expres-
sion of inhibitors of apoptosis [17].
In the immune system IL-33, through its receptor T1/
ST2 (transmembrane form of ST2), exerts a pivotal role
in Th2 responses, as well as in mast cell and eosinophil
activation through activation of NF-kB and MAP
Kinases [18-20]. Soluble ST2 levels have been found ele-
vated in an array of human diseases including asthma,
allergic airway inflammation, systemic lupus erythemato-
sus, rheumatoid arthritis, idiopathic pulmonary fibrosis
and sepsis. Several studies have also shown a beneficial
effect after soluble ST2 administration in animal models
of inflammatory disease [18]. These results have been
attributed to the blockade of IL 33 actions with down-
stream suppression of NF-kB activation [18].
In relation to diabetes, IL33 exerted protective effects
in an animal model of obese diabetic mice (ob/ob) redu-
cing adiposity, fasting plasma glucose and improving
glucose tolerance and insulin resistance [21].
In the present study we investigated the differences in
the levels of soluble ST2, B-type natriuretic peptide
(BNP) and high sensitivity C - reactive protein (hs-CRP)
between healthy controls and patients with type 2 dia-
betes with and without left ventricular diastolic dysfunc-
tion (LVDD). A secondary aim was to investigate
correlations between sST2 and other biomarkers of type
2 diabetes, such as glycosylated hemoglobin (HbA1c).
Methods
This is a prospectively conducted study that took place
in an urban general hospital in Piraeus, Greece from
July 2009 to July 2010. The study protocol is in compli-
ance with the Helsinki Declaration and was approved by
the ethical committee of the hospital (5/10-04-2009).
The diabetic population of our sample was recruited
from the Diabetes Center of our hospital. People with
type 2 diabetes were informed about the study protocol
and were voluntarily recruited after consent. People
without diabetes (controls) were chosen from the echo-
cardiography unit of the cardiology department of the
same hospital among patients without history of cardiac
diseases, in whom the indication for echocardiography
was “atypical chest pain”. They were also voluntarily
recruited after informed consent.
Subjects with impaired systolic function (ejection frac-
tion of left ventricle < 50%) or history of coronary artery
disease were excluded. Other exclusion criteria included
history of: arrhythmias, cardiac valvular disorders, malig-
nancies, autoimmune diseases and other inflammatory
states, Cushing’s syndrome and use of corticosteroids or
thiazolinediones.
Subjects underwent a complete Doppler-echocardio-
graphic evaluation. Echocardiography (and especially
Tissue Doppler Imaging) was used to diagnose subjects
with left ventricular systolic and/or diastolic dysfunction
(according to the revised guidelines of A.C.C./A.H.A.
2009). Studies were performed on a Vivid 7 echocardio-
graphy machine (Vingmed, Norway). All measurements
were made by a single experienced echocardiographer
blinded to the diabetic status of the patients according
to the ASE recommendations for chamber quantification
20051. The LV ejection fraction was estimated using the
Simpson biplane method. From the mitral inflow profile,
the E- and A-wave peak velocities and DT were mea-
sured. The E’ velocity from the septal and lateral mitral
valve annulus and the mean value were determined, and
t h er e s p e c t i v eE / E ’ ratios were derived. An E/E’septal
ratio >15 was considered indicative of elevated LV filling
pressure. Diastolic function was categorized using mitral
inflow and Doppler Tissue Imaging parameters. Grade
3 diastolic dysfunction (restrictive) was defined as an E/
A ratio >2 and/or DT <150 milliseconds; and Grade 1
dysfunction (impaired relaxation), as an E/A ratio <1
and/or a DT >220 milliseconds. Grade 2 dysfunction
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between 150 and 220 milliseconds and the E/A ratio
was between 1 and 2, but either the E/e’septal was >10
and/or the E/A ratio fell to <1 with Valsalva. Remaining
subjects were categorized as having normal diastolic
function.
Finally, 158 Caucasian volunteers [60 subjects without
diabetes and 98 patients with type 2 diabetes, mean age
± standard deviation (SD) 56.24 ± 9.78 years] were
included (convenient sample). Echocardiograms allowed
the division of the study population in 4 groups: Group
A: 42 healthy controls, Group B: 18 subjects without
diabetes with LVDD, Group C:4 8p a t i e n t sw i t ht y p e2
diabetes without LVDD, Group D: 50 patients with type
2 diabetes & LVDD.
Height and weight were measured in all subjects to cal-
culate the Body Mass Index (BMI in Kg/m
2). Fasting
blood samples were analyzed for: fasting plasma glucose
(FPG), urea & creatinine [in order to estimate glomerular
filtration rate (eGFR) according to the Cockroft-Gault for-
mula], total Cholesterol, high density lipoproteins (HDL),
low density lipoproteins (LDL), triglycerides, BNP, hs-
CRP, HbA1c and fibrinogen, using the standard proce-
dures of the biochemistry laboratory of our hospital.
The serum of the participants was kept at -70°C and
was processed within 6 months after sampling using the
Presage
® ST2 ELISA kit (Critical Diagnostics, U.S.A.) in
order to measure the Soluble ST2 levels.
Statistical analysis was performed with Kruskal-Wallis
test & Mann-Whitney test (for continuous variables)
and x
2 test or Fischer exact test (for discrete variables).
Spearman coefficient was used for the univariate analy-
sis, whereas the step-wise backward method for the
multivariate analysis. The main study hypothesis was
that sST2 levels differed significantly among the 4 study
groups (H1).
Results
Age, sex and duration of diabetes did not differ signifi-
cantly among the study groups. Statistical variability was
only observed for mean BMI among the study groups
(table 1) with group A to present lower mean BMI
values compared with groups B (p = 0,001) and D (p =
0,002). Univariate analysis, though, in groups C and D
(patients with type 2 diabetes) did not prove that BMI
impact on the circulating sST2 levels. The subjects of
groups B & D (LVDD present) had more frequently his-
tory of hypertension (for B: 66.7% & D: 76%) in relation
to the remaining 2 groups (LVDD absent). Additionally
all members of groups B and D exhibited the impaired
relaxation pattern (grade 1 LVDD) in the
echocardiograms.
Significant variability among the 4 study groups was
observed for the mean values of sST2 (p < 0.001), hs-
CRP (p = 0.039), FPG (p < 0.001), total Cholesterol (p <
0.001), HDL (p < 0.001), LDL (p < 0.001), triglycerides
(p = 0.002) and HbA1c (p < 0.001). Mean HbA1c of
Group A was 6,08%, Group B 6,46%, Group C 8,67%
and Group D 7,92%. Mean HbA1c of non-diabetic
population was significantly lower than the correspon-
dent of patients with type 2 diabetes, as expected. Mean
HbA1c of Group C did not differ statistically compared
to the correspondent of Group D (p = 0,157). No varia-
bility was found for the mean values of BNP (p =
0.301), fibrinogen (p = 0.302) and eGFR (p = 0.393)
(table 2).
Soluble ST2 (mean ± SD) was 9.16 ± 4.56 ng/ml for
healthy controls (Group A), 9.93 ± 3.57 ng/ml for sub-
jects without diabetes with LVDD (Group B), 11.31 ±
3.05 ng/ml for patients with type 2 diabetes without
LVDD (Group C) and 14.97 ± 5.23 ng/ml for patients
with type 2 diabetes & LVDD (Group D) (Figure 1).
Soluble ST2 levels did not differ significantly between
groups A and B (subjects without diabetes) (p = 0.514).
Statistically significant difference was observed between
healthy controls (group A) and patients with type 2
Table 1 Demographic characteristics of the study
population
VARIABLE GROUP Mean S.D. p-value
AGE
(years)
A 55,10 10,50 0,107
B 60,33 9,65
C 54,87 9,94
D 56,98 8,80
TOTAL 56,24 9,78
SEX
(% males)
A 61,90 NA 0,081
B 77,80 NA
C 45,80 NA
D 50,00 NA
TOTAL 58,90 NA
DURATION OF DIABETES (years) A NA NA 0,136
BN A N A
C 2,81 2,50
D 4,97 6,03
BMI
(Kg/m
2)
A 27,83 4,62 0,005
B 32,63 6,45
C 29,41 5,13
D 31,69 7,77
We used the Kruskal-Wallis test to analyze the variability of age, duration of
diabetes & BMI and the chi squared test to analyze the sex variability
between the 4 study groups. P-value found significant only for BMI, where the
relative value of group A was significantly lesser than the correspondent of
group B (p = 0,001) and group D (p = 0,002). All the other possible
comparisons of BMI were found to be statistically insignificant. (NA = Not
applicable)
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over, patients with type 2 diabetes with LVDD (group
D) had the highest serum levels of sST2 among the 4
study groups (table 3).
The respective mean values of BNP for the 4 study
groups were: A: 28.78 ± 13.73 pg/ml, B: 33.37 ± 19.88
pg/ml, C: 40.06 ± 31.39 pg/ml and D: 29.63 ± 22.55 pg/
ml without statistically significant differences between
the 4 study groups (table 3).
The mean hs-CRP of group A was 3,04 ± 4,44 mg/l,
group B 3,34 ± 4,87 mg/l, group C 5,61 ± 6,21 mg/l and
group D 6,35 ± 7,79 mg/l. No difference was found for
the mean values of hs-CRP between groups A vs Ba n d
C vs D. All subjects with type 2 diabetes (Groups C and
D) presented higher hs-CRP levels compared to the
non-diabetic population (Groups A and B) of the study
(table 3).
Figure 1 Mean sST2 value for each study group. Patients with
type 2 diabetes and left ventricular diastolic dysfunction have the
highest mean sST2 (14.97 ± 5.23 ng/ml) among the 4 study groups,
even higher than the correspondent of 11.31 ± 3.05 ng/ml of
patients with type 2 diabetes without left ventricular diastolic
dysfunction (p = 0.001). Furthermore, both 14.97 ± 5.23 ng/ml &
11.31 ± 3.05 ng/ml are higher than the correspondent of those
subjects without diabetes. Mean sST2 at 9.16 ± 4.56 ng/ml of
healthy controls does not statistically differ compared to the
correspondent of 9.93 ± 3.57 ng/ml of subjects without diabetes
with left ventricular diastolic dysfunction (p = 0.514).
Table 2 Results of the study’s parameters
VARIABLE GROUP Mean S.D. p-value
Soluble ST2 (ng/ml) A 9,16 4,56 <0,001
B 9,93 3,57
C 11,31 3,05
D 14,97 5,23
BNP (pg/ml) A 28,78 13,73 0,301
B 33,37 19,88
C 40,06 31,39
D 29,63 22,55
hs-CRP
(mg/lt)
A 3,04 4,45 0,039
B 3,34 4,87
C 5,61 6,21
D 6,35 5,79
Fibrinogen
(gr/lt)
A 4,00 0,81 0,302
B 3,84 0,60
C 4,35 1,55
D 3,82 1,21
Fasting Plasma Glucose
(mg/dl)
A 94,71 10,24 <0,001
B 100,00 11,48
C 137,75 37,59
D 136,54 30,05
eGFR
(mlt/min)
A 106,70 27,05 0,393
B 107,44 27,90
C 120,58 44,68
D 124,50 43,61
Total Cholesterol (mg/dl) A 211,57 34,83 <0,001
B 222,00 44,74
C 208,88 44,95
D 173,64 39,03
HDL
(mg/dl)
A 51,24 11,67 <0,001
B 49,33 14,42
C 47,25 15,97
D 39,60 9,96
LDL
(mg/dl)
A 136,83 30,12 <0,001
B 143,84 36,66
C 137,13 37,22
D 101,22 36,66
Triglycerides (mg/dl) A 116,52 43,80 0,002
B 148,56 47,83
C 124,25 52,77
D 159,30 73,90
HbA1c
(%)
A 6,08 0,36 <0,001
B 6,46 0,38
Table 2 Results of the study?’?s parameters (Continued)
C 8,67 2,08
D 7,92 1,21
We used the Kruskal-Wallis test to analyze the variability of the continuous
variables of the study. Significant variability among the 4 study groups was
noted for the mean values of sST2, hs-CRP, FPG, total Cholesterol, HDL, LDL,
Triglycerides and HbA1c. No variability was found for the mean values of BNP,
fibrinogen and eGFR.
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betes without LVDD), univariate analysis showed that
sST2 levels correlated positively with hs-CRP levels (p =
0.04), fibrinogen (p = 0.027), fasting plasma glucose
(FPG) (p < 0.01), HbA1c (p < 0.01) and negatively corre-
lated with the HDL (p < 0.01), sex (females) (p < 0.01),
history of hypertension (p = 0.045) and chronic obstruc-
tive pulmonary disease (p = 0.01). No correlation was
confirmed between sST2 and age (p = 0.513), BMI (p =
0.603), duration of diabetes (p = 0.297), BNP (p =
0.512), eGFR (p = 0.070), total Cholesterol (p = 0.580),
LDL (p = 0.613), Triglycerides (p = 0.091). Multivariate
analysis manifested HDL, HbA1c, sex, history of hyper-
tension and COPD as the most powerful and indepen-
dent parameters of sST2, that predict and/or interpret
the 81% of sST2 variability in this group.
Similar statistical analysis in Group D (patients with
type 2 diabetes & LVDD) revealed that sST2 levels posi-
tively correlated with HbA1c (p < 0,01) and hs-CRP
levels (p = 0,042) and negatively only with HDL (p =
0.041). Multivariate analysis, though, manifested solely
HbA1c as the unique independent parameter that affects
the serum ST2 value in group D.
Discussion
The results of the present study indicate that type 2 dia-
betes (with or without LVDD) is connected with higher
sST2 levels that positively correlate with hs-CRP levels
and the extend of glycemic control (ΗbA1c).
Today it is known that type 2 diabetes is associated
with low-grade chronic inflammation that in part ema-
nates from activation of the innate immune system [22]
that gives rise to the acute phase response in which
CRP plays a fundamental role [22] and several studies
have documented the connection between high CRP
levels and type 2 diabetes in the presence or absence of
obesity [23,24]. Soluble ST2 levels have also been found
elevated in numerous inflammatory disorders which are
thought to exert a protective effect and from this point
of view the correlation of sST2 levels with CRP levels in
diabetics in our study most possibly reflects the inflam-
matory component of diabetes. In this context, increased
sST2 levels represent a counterregulatory mechanism to
chronic inflammation. In accordance with the above
speculation is also the observed correlation between
sST2 levels and extent of glycemic control as indicated
by HbA1c levels.
Patients with type 2 diabetes and grade 1 LVDD, an
early finding of diabetic cardiomyopathy [25,26], exhib-
ited the highest sST2 levels in our study. The lack of
diabetic patients with higher grades of LVDD did not
allow further remarks on the quantitative relationship
between sST2 levels and the grade of LVDD in the pre-
sent study and further research is needed at this point.
The increased sST2 levels in patients with diabetes and
LVDD cannot be attributed to chronic inflammation or
increased glycemic burden since no statistically signifi-
cant differences for hs- CRP and HbA1c have been
observed between the two groups of diabetic patients.
Several studies have established the prognostic role of
sST2 levels in myocardial infarction, heart failure, right
ventricle function and dyspneic states, while there are no
available data about IL-33 levels in cardiovascular disor-
ders [13]. Today studies from animal models suggest that
sST2 is more than just a marker in cardiovascular disease
and implicate IL33/ST2 signaling as an important protec-
tive pathway in which the role of sST2 remains obscure
[13]. In states of oxidative stress as in diabetes increased
expression of endothelin 1 has been found paradoxically
to restore diastolic dysfunction [27] and endothelin 1 is a
known inducer of sST2 expression and inhibitor of IL-33
signaling through p38 MAPK [28]. From this point of
view, increased levels of sST2 in patients with diabetes and
LVDD might be an epiphenomenon of other counteregu-
latory mechanisms such as endothelin 1 or to signify
patients with failure of IL-33-induced cardioprotection,
through sST2 acting as a decoy receptor.
TLRs are broadly distributed on immune cells and
represent primordial recognition receptors mediating
activation of the innate immune system [29]. Several
recent studies have revealed attenuation of TLR4 and
TLR2 signaling by the ST2 pathway with subsequent
diminished production of proinflammatory cytokines
[30-32]. In relation to infectious disease administration
of sST2 protects mice against endotoxin-induced shock
[31] and the IL-33/ST2 signaling pathway also prevents
an inappropriate parasite specific Th1 polarized
response by induction of IL-4, IL-9 and IL-13 [33] and
the above findings suggest a major regulatory role of the
Table 3 Comparison of mean value of sST2, BNP and hs-
CRP between the 4 study groups
Comparison p-value
sST2 BNP hs-CRP
A vs B 0,514 0,628 0,872
Av sC 0,007 0,213 0,004
Av sD <0,001 0,207 0,017
B vs C 0,121 0,863 0,041
Bv sD <0,001 0,504 0,048
Cv sD 0,001 0,091 0,659
Overall <0,001 0,301 0,039
Soluble ST2 was significantly different between group A (healthy controls) and
patients with type 2 diabetes without (group C) LVDD (p = 0.007). Moreover,
patients with type 2 diabetes with LVDD (group D) had the highest mean
serum level of sST2 compared to the correspondent of the rest 3 subject
groups: group A (p < 0.001), group B (p < 0.001) and group C (p = 0.001). The
respective mean values of BNP for the 4 study groups could not achieve
statistical difference. All subjects with type 2 diabetes presented higher hs-
CRP levels compared to the non-diabetic population of the study.
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response.
IL-33/ST2 signaling is also implicated in autoimmune
disease and in an experimental animal model of diabetes
I induction by multiple doses of streptozotocin this
pathway seems to exert a protective effect possible
through balancing Th1/Th2 response [34]. Additionally
endothelial cells from type I diabetic mice have been
found to exhibit enhanced inflammatory responses after
stimulation of TLR2 and TLR 4 through augmented
NF-kB activation [35].
The role of IL-33/ST2 pathway in type I and II diabetes
remains vastly unknown today. In type II diabetes the
molecular mechanisms that induce inflammatory media-
tors are still being elucidated and TLRs are considered
primary effector molecules in this process that are also
activated by nutritional factors as FFA. Ligand binding by
TLRs triggers the inflammatory cascade and insulin
homeostasis dysregulation [22]. Apart from the innate
immune system the adaptive immunity seems also to be
implicated in the chronic inflammation of type II diabetes
and CD4-positive T lymphocytes are the first cells to
infiltrate fat tissue [36]. From this point of view IL-33/
ST2 pathway might prove to be a crucial pathway in bal-
ancing the intensity of inflammation in diabetes.
Subjects without diabetes ± LVDD exhibited similar
mean serum ST2 values and this underlines the fact that
sST2 does not represent a mere index of diastolic dys-
function but rather an indicator of a deranged metabolic
environment of chronic inflammation and oxidative
stress in which cardiovascular damage develops.
In conclusion, this is the first study to document ele-
vated sST2 levels in type 2 diabetes. Chronic inflamma-
tion most possibly establishes the basis of increased
soluble ST2 levels and diastolic dysfunction seems also
to be connected with further increase of this biomarker
with still obscure mechanisms.
Conclusion
This is the first study to document increased levels of
soluble ST2 in patients with type 2 diabetes in general
with higher elevations in the presence of LVDD. Further
research with bigger populations needs to be done in
order to abut on more general conclusions.
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